



## Clinical manifestations in individuals with recent diagnosis of HTLV type I infection

Shelene K.W. Poetker<sup>a,b,c</sup>, Aurelia F. Porto<sup>a</sup>, Silvana P. Giozza<sup>a</sup>, Andre L. Muniz<sup>a</sup>, Marina F. Caskey<sup>b</sup>, Edgar M. Carvalho<sup>a,d</sup>, Marshall J. Glesby<sup>b,\*</sup>

<sup>a</sup> Serviço de Imunologia do Hospital Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil

<sup>b</sup> Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, United States

<sup>c</sup> Department of Internal Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, United States

<sup>d</sup> Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais (CNPq/MCT), Brazil

### ARTICLE INFO

#### Article history:

Received 21 November 2010

Received in revised form 7 January 2011

Accepted 7 February 2011

#### Keywords:

HTLV-1

Neurologic manifestations

Clinical manifestations

Neuropathy

Natural history

### ABSTRACT

**Background:** Human T-lymphotropic virus type 1 (HTLV-1) is known to cause HTLV-associated myelopathy (HAM)/tropical spastic paraparesis and adult T cell leukemia. A growing body of evidence links HTLV-1 infection with an increasing spectrum of disease, including uveitis, periodontal disease, arthropathy, sicca syndrome, and neurologic deficits.

**Objectives:** Despite recent findings, the natural history of HTLV-1 infection remains poorly defined. This study was designed to better characterize initial clinical and neurological findings in individuals diagnosed with HTLV-1 infection.

**Study design:** We conducted a cross-sectional study of 71 individuals recently diagnosed with HTLV-1 and 71 uninfected age- and sex-matched blood donors in Salvador, Brazil. Subjects were administered a standardized questionnaire and underwent physical exam.

**Results:** HTLV-1 infected subjects were significantly more likely than controls to report complaints of hand and foot numbness (OR=5.3; 95% CI: 1.8–15.3;  $p=0.002$  and OR=4.0; 95% CI: 1.3–12;  $p=0.013$  respectively), difficulty running (OR=4.0; 95% CI: 1.1–14.2;  $p=0.032$ ), nocturia (OR=5.0; 95% CI: 1.1–22.8;  $p=0.038$ ), arthralgia (OR=3.3; 95% CI: 1.4–7.7;  $p=0.006$ ), and photophobia (OR=3.3; 95% CI: 1.4–7.7;  $p=0.006$ ).

**Conclusions:** Neurologic, ocular and rheumatologic complaints may be the first manifestations of HTLV-1 infection. Therefore, all patients presenting with initial diagnosis should be rigorously screened for these symptoms.

© 2011 Elsevier B.V. All rights reserved.

## 1. Background

It is estimated that 15–20 million people are currently infected with human T-cell lymphotropic virus type 1 (HTLV-1) worldwide,<sup>1</sup> clustered in Africa, Central and South America, and Japan.<sup>2</sup> Because its best-known complications, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult

T cell leukemia/lymphoma (ATLL), occur in less than 5% of infected individuals, HTLV-1 infection has been associated traditionally with low morbidity.<sup>3–7</sup> However recent research has revealed biologic and epidemiologic evidence of association with a wider disease spectrum,<sup>8</sup> including uveitis,<sup>9–11</sup> polymyositis,<sup>12,13</sup> arthropathy,<sup>14,15</sup> and sicca syndrome.<sup>16</sup> In addition, multiple neurologic abnormalities, including erectile dysfunction,<sup>17</sup> overactive bladder,<sup>18</sup> weakness, hyperreflexia<sup>19</sup> and peripheral neuropathy<sup>21–23</sup> occur in HTLV-1 infected individuals without overt myelopathy, increasing the lifetime risk of HTLV-1-associated disease to greater than 30%.<sup>8</sup>

We previously reported a cross-sectional study demonstrating that HTLV-1 infected carriers were more likely than seronegative controls to report arm or leg weakness, hand or foot numbness, arthralgias, nocturia, and erectile dysfunction and to have gingivitis, periodontitis, and dry oral mucosa.<sup>23</sup> However, this study was limited by the fact that HTLV-1 infected subjects were, on average, older than controls and were recruited from a HTLV-1 clinic where

**Abbreviations:** ATL, adult T-cell leukemia/lymphoma; CI, confidence interval; CNS, central nervous system; HAM/TSP, human T-lymphocytic virus-associated myelopathy/tropical spastic paraparesis; HTLV-1, human T-lymphotropic virus type 1; INF-gamma, interferon-gamma; TNF-alpha, tumor necrosis factor-alpha; OR, odds ratio; OR<sup>a</sup>, adjusted odds ratio.

\* Corresponding author at: Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, 525 East 68th St., Box 566, New York, NY 10065, United States. Tel.: +1 212 746 4177; fax: +1 212 746 8852.

E-mail address: [mag2005@med.cornell.edu](mailto:mag2005@med.cornell.edu) (M.J. Glesby).

**Table 1**  
Demographic characteristics of HTLV-1 infected cases and uninfected controls.

	Case	Control	Matched OR <sup>a</sup>	95% CI	<i>p</i>
<i>N</i>	71	71			
Gender					
Male (%)	26 (36.6%)	26 (36.6%)			
Age (years), mean (SD)	40.2 (11.7)	40.3 (11.7)			0.96
Race (%)					
White	15 (21.7%)	14 (20%)	Referent		
Mulatto	19 (27.5%)	24 (34.3%)	0.57	0.21–1.5	0.27
Black	34 (49.3%)	28 (40%)	0.95	0.41–2.2	0.91
Other	1 (1.5%)	4 (5.7%)	0.17	0.02–1.8	0.14
Education (%)					
<8 years	26 (40%)	6 (12%)	Referent		
>8 years	39 (60%)	44 (88%)	0.14	0.03–0.63	0.01
Income (%)					
<4 × MW <sup>b</sup>	61 (87.1%)	50 (71.4%)	Referent		
>4 × MW	9 (12.9%)	20 (28.6%)	0.42	0.18–0.96	0.04

<sup>a</sup> Conditional logistic regression.

<sup>b</sup> Minimum wage is equivalent to US\$291.50 per month.

many had been followed long term, creating a potential selection bias.

## 2. Objectives

To better determine the prevalence of HTLV-1-associated disease and characterize early clinical and neurological findings, we conducted a cross-sectional study of individuals recently diagnosed with HTLV-1 and uninfected blood donors in Salvador, Brazil.

## 3. Study design

### 3.1. Study site and population

This study was performed in Salvador, the capital city of Bahia State, in Northeastern Brazil, reported to have a seroprevalence of HTLV-1 infection of 1.76%.<sup>24,25</sup>

### 3.2. Study design and participants

Cases were patients referred to the HTLV-1 clinic at the Hospital Universitário Prof. Edgard Santos from blood banks in Salvador, prenatal clinics, or through recent diagnosis of a family member. All new cases referred from January 2006 through July 2008, with serologic diagnosis by ELISA (Cambridge Biotech Corp., Worcester, MA) within the previous six months, were evaluated for inclusion. Inclusion criteria included confirmation of HTLV-1 diagnosis by Western Blot analysis (HTLV blot 2.4, Genelab, Singapore) and age between 18 and 60 years. Exclusion criteria included diagnosis of HAM/TSP,<sup>26</sup> Hepatitis C or HIV infection, positive VDRL, and diabetes mellitus.

Seronegative controls were recruited from one of the three major blood banks in Salvador (STS) at the time of blood donation, and matched 1:1 to cases by age ( $\pm 5$  years) and sex. The study was approved by the Institutional Review Boards of the Hospital Universitário Prof. Edgard Santos and Weill Cornell Medical College. Informed consent was obtained from all subjects enrolled in the study.

### 3.3. Evaluations

A standardized questionnaire<sup>23</sup> was administered to all cases on first presentation to the HTLV-1 clinic. Controls were administered the same questionnaire at the time of blood donation. All subjects underwent dental, rheumatological, and neurological examinations by a trained internist (S.P.). Exams were not blinded

to HTLV-1 status because the subjects were aware of their infection status. Most patients with new diagnosis had no previous knowledge of the virus, and counseling was provided during interviews.

### 3.4. Statistical analysis

All analyses were performed using Stata 9.1 software (Stata Corporation, College Station, TX). Continuous variables were analyzed with an independent samples *t*-test. Matched univariate odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by conditional logistic regression for all variables with binary outcomes. Multiple conditional logistic regression was used to adjust for potential confounders. A *p* value of <0.05 was considered significant for statistical tests. No adjustment was made for multiple comparisons.

## 4. Results

Of 85 patients referred to the HTLV-1 clinic with new HTLV-1 diagnosis between January 2006 and July 2008, 72 cases met inclusion and exclusion criteria and were included in the study. Of these, 7 patients were referred from a prenatal clinic and one through diagnosis of a related blood donor. Demographic characteristics for these individuals were not statistically different than those of blood donors, and they were included in analysis. The remaining 64 patients were referred by blood banks. Given a limitation in the number of age-matched controls, 18 controls recruited by another study-trained internist (M.F.C.) between 2004 and 2005 at the same blood bank were included in the study; only questionnaire data for these patients were used in the analysis. No control was available for one remaining case, thus leaving 71 cases of HTLV-1 infected blood donors, and 71 uninfected controls.

Table 1 summarizes the baseline characteristics of the study population. Case and control subjects were comparable with respect to age and ethnicity. HTLV-1 seronegative controls had a significantly higher socioeconomic status, determined by education and income. Each of these variables was analyzed as a potential confounder. Although education showed the strongest independent association with HTLV status (*p*=0.01), this variable was unavailable for a large proportion of controls. Consequently, all analyses were adjusted for income level (*p*=0.04), known for almost all participants.

As summarized in Table 2, HTLV-1 infected subjects were significantly more likely than controls to report complaints of hand and foot numbness (OR=5.3; 95% CI: 1.8–15.3; *p*=0.002 and OR=4.0; 95% CI: 1.3–12; *p*=0.013 respectively), difficulty running (OR=4.0;

**Table 2**  
Univariate and multivariate analyses of symptoms reported by HTLV-1 infected cases and uninfected controls.

Symptoms	Case	Control	OR <sup>a</sup>	95% CI	<i>p</i>	Adjusted OR <sup>b</sup>	95% CI	<i>p</i>
Neurologic	<i>n</i> = 71	<i>n</i> = 71						
Hand numbness	25 (35.2%)	8 (11.3%)	5.3	1.8–15.3	0.002	7.0	2–23.6	0.002
Foot numbness	17 (23.9%)	5 (7%)	4.0	1.3–12	0.013	6.1	1.7–22	0.005
Arm weakness	10 (14.1%)	1 (1.4%)	–	–	–	–	–	–
Leg weakness	9 (12.7%)	1 (1.4%)	–	–	–	–	–	–
Difficulty walking	8 (11.3%)	0 (0%)	–	–	–	–	–	–
Difficulty running	12 (16.9%)	3 (4.2%)	4.0	1.1–14.2	0.032	4.0	1.1–14.8	0.038
Urologic	<i>n</i> = 71	<i>n</i> = 71						
Frequency	11 (15.5%)	20 (28.2%)	0.5	0.22–1.1	0.09	0.57	0.25–1.3	0.18
Nocturia	14 (19.7%)	6 (8.5%)	5.0	1.1–22.8	0.038	4.1	0.88–19.1	0.073
Urgency	12 (16.9%)	5 (7%)	2.8	0.88–8.6	0.083	3.0	0.81–11.1	0.101
Incontinence	10 (14.1%)	3 (4.2%)	3.3	0.92–12.1	0.067	3.0	0.8–11.3	0.105
Rheumatologic	<i>n</i> = 71	<i>n</i> = 71						
Arthralgia	25 (35.3%)	9 (12.7%)	3.3	1.4–7.7	0.006	3.5	1.4–8.5	0.005
Dental	<i>n</i> = 71	<i>n</i> = 71						
Xerostomia	16 (22.5%)	11 (15.5%)	1.5	0.67–3.3	0.321	1.6	0.7–3.6	0.27
Gingival bleeding	18 (25.4%)	11 (15.5%)	2.0	0.81–5	0.13	2.1	0.82–5.4	0.12
Ocular	<i>n</i> = 71	<i>n</i> = 71						
Dry eyes	14 (19.7%)	24 (33.8%)	0.52	0.25–1.1	0.082	0.59	0.28–1.2	0.17
Painful eyes	17 (23.9%)	14 (19.7%)	1.3	0.56–3.2	0.51	1.6	0.65–4	0.30
Photophobia	24 (33.8%)	8 (11.3%)	3.3	1.4–7.7	0.006	4.0	1.6–10.1	0.003
Sexual	<i>n</i> = 25	<i>n</i> = 24						
Erectile dysfunction	6 (24%)	2 (8.3%)	3.0	0.61–14.9	0.178	3.0	0.61–14.9	0.18

<sup>a</sup> Matched OR by conditional logistic regression.

<sup>b</sup> Matched OR after adjustment for income.

95% CI: 1.1–14.2; *p* = 0.032), nocturia (OR = 5.0; 95% CI: 1.1–22.8; *p* = 0.038), arthralgia (OR = 3.3; 95% CI: 1.4–7.7; *p* = 0.006), and photophobia (OR = 3.3; 95% CI: 1.4–7.7; *p* = 0.006). A higher percentage of subjects among cases than controls complained of arm and leg weakness (14.1% and 12.7% vs. 1.4% respectively) and of difficulty with ambulation (11.3% vs. 0%). A trend toward association between HTLV-1 infection and incontinence was also noted (OR = 3.3; 95% CI: 0.92–12.1; *p* = 0.067). In multivariate analysis, when data were adjusted for income, HTLV-1 infected subjects remained more likely to report nocturia (OR<sup>a</sup> = 4.0; 95% CI 0.88–19.1) but this difference was no longer statistically significant (*p* = 0.073). All other associations remained statistically significant.

Table 3 summarizes findings on physical examination. Despite the higher prevalence of several subjective findings among HTLV-1 infected cases, objective physical exam failed to show any statistically significant differences between cases and seronegative controls. However, several important trends were noted. Two cases of weakness (3%) were noted among HTLV-1 infected subjects; no such cases were found among controls. A trend toward hyperreflexia was also observed among HTLV-1 infected patients (OR = 2.8; 95% CI: 0.88–8.6; *p* = 0.083). Decreased range of motion on rheumatologic exam was more common among seropositive subjects (7.4% vs. 0%), though this was not accompanied by signs of inflammation such as edema or warmth. Of note, no significant

difference was noted between HTLV-1 infected and uninfected subjects in prevalence of periodontitis or dry mucosa.

## 5. Discussion

Over the last ten years, evidence has accumulated that, in addition to HAM/TSP and ATLL, HTLV-1 infection is capable of causing a variety of diseases including uveitis,<sup>9–11</sup> periodontal disease,<sup>23,27</sup> sicca syndrome,<sup>16</sup> HTLV-1 associated arthropathy,<sup>14,15</sup> and a large number of neurologic deficits.<sup>17–22</sup> It is particularly striking that these findings occur in a large group of individuals traditionally considered to be asymptomatic HTLV-1 carriers, indicating that morbidity associated with HTLV-1 is much higher than that has been previously considered.<sup>19,28–31</sup> Despite these contributions very little is known about the natural history of HTLV-1 infection. Specifically there is a gap related to information regarding the time between infection and appearance of objective clinical manifestations. In the present study we demonstrate that, in individuals with recently diagnosed HTLV-1 infection, subjective hand and feet numbness, arm and leg weakness, difficulty with ambulation and running, arthralgia, and photophobia were more frequent than in seronegative controls. However, given the unknown duration of infection prior to detection, we cannot determine conclusively that these are true early manifestations of infection.

**Table 3**  
Univariate and multivariate analyses of physical findings in HTLV-1 infected cases and uninfected controls.

Findings	Case	Control	OR <sup>a</sup>	95% CI	<i>p</i>	Adjusted OR <sup>b</sup>	95% CI	<i>p</i>
Neurologic (%)	<i>n</i> = 66	<i>n</i> = 53						
Weakness	2 (3%)	0 (0%)	–	–	–	–	–	–
Hyperreflexia	14 (21.2%)	4 (7.5%)	2.8	0.88–8.6	0.083	2.8	0.88–8.7	0.082
Babinski	5 (7.6%)	2 (3.8%)	2.0	0.37–10.9	0.42	2.2	0.39–12.9	0.36
Rheumatologic	<i>n</i> = 54	<i>n</i> = 53						
Edema/warmth	1 (1.9%)	1 (1.5%)	1.0	0.06–16	1	1.0	0.06–16	1.0
Decreased ROM <sup>c</sup>	4 (7.4%)	0 (0%)	–	–	–	–	–	–
Dental	<i>n</i> = 61	<i>n</i> = 53						
Periodontitis	15 (24.6%)	15 (28.8%)	0.7	0.27–1.8	0.47	0.45	0.15–1.4	0.17
Dry mucosa	33 (54.1%)	27 (50.1%)	1.6	0.61–4.1	0.35	1.8	0.66–5	0.24

<sup>a</sup> Matched OR by conditional logistic regression.

<sup>b</sup> Matched OR after adjustment for income.

<sup>c</sup> Range of motion.

The pathogenesis of diseases associated with HTLV-1 has been correlated with an elevated proviral load and an exaggerated type 1 immune response leading to inflammatory changes and adjacent tissue damage.<sup>32,33</sup> These mechanisms have been documented not only in HAM/TSP, but also in other diseases associated with HTLV-1 infection, including infective dermatitis,<sup>34</sup> periodontal disease,<sup>27</sup> HTLV-1-associated arthropathy,<sup>35</sup> sicca syndrome,<sup>16</sup> and isolated neurologic deficits.<sup>36</sup> These findings clearly implicate HTLV-1 infection as central to the observed clinical pathology. Particularly pertinent to our findings is the fact that elevated levels of inflammatory cytokines such as INF-gamma, TNF-alpha, and chemokines have also been observed in up to 40% of asymptomatic carriers.<sup>37–39</sup> Further research is required to determine whether these serologic markers are risk factors for the development of future subjective or objective findings.

Compared with our previous cross-sectional study analyzing HTLV-1 carriers followed long term in a HTLV-1 clinic and seronegative controls,<sup>23</sup> we observed that, while neurologic complaints and arthralgia remained significantly more frequent in individuals with recent HTLV-1 diagnosis, increased prevalence of other manifestations such as overactive bladder, erectile dysfunction, and xerostomia did not reach statistical significance. It is possible that the reduced number of cases included in this study resulted in insufficient power to detect less marked differences. Alternatively, there may have been differences in self-report of symptoms related to differences in educational status between cases and controls. It is also possible that the manifestations detected in this study are, in fact, the early manifestations of HTLV-1 infection in this population, while periodontal disease, salivary gland involvement, and symptoms of overactive bladder and erectile dysfunction may occur later in the infection. The absence of data on the duration of infection, however, precludes us from concluding this definitively.

The primary challenge in characterizing the natural history of HTLV-1 infection is that the time of infection cannot be determined in the large majority of infected individuals. As the majority of participants in this study were blood bank donors, the likelihood of transmission by injection drug use or transfusion is diminished; indeed, epidemiologic studies confirm low prevalences of both risk factors in our population.<sup>40</sup> Thus, it is probable that the majority were infected by either breast feeding or sexual transmission, both of which are associated with a slow, progressive course of disease.<sup>8</sup>

The symptoms described by HTLV-1 carriers in this study may be attributable to known HTLV-1 pathology. For example, the subjective symptoms of numbness and weakness are traditionally ascribed clinically to peripheral neuropathy, previously described in HTLV-1 carriers, though recently with some controversy. However, such symptoms are also observed in syndromes involving the central nervous system (CNS). In fact, MRI abnormalities observed in HAM/TSP are also detected in HTLV-1 carriers, suggesting that CNS, particularly spinal cord, involvement may contribute to these neurologic manifestations.<sup>41,42</sup> Similarly, HTLV-1 infected patients with complaints of photophobia and arthralgia may be at higher risk of developing ocular or rheumatologic manifestations of HTLV-1 respectively.

Our data demonstrate the importance of studying individuals in the early phase of clinical disease in order to better clarify the natural history of HTLV-1 infection. The onset of the various manifestations associated with HTLV-1 likely occurs at different periods during the course of infection. Our findings suggest that weakness, sensory abnormalities, and ocular and rheumatologic complaints may be the first manifestations of HTLV-1 infection to come to clinical attention. Therefore, all patients presenting with initial diagnosis should be rigorously screened for these symptoms.

## Funding

National Institutes of Health (Grants R01-079238 and NIAID K24 AI078884), Fogarty International Center (R24 TW007988).

## Competing interests

None declared.

## Ethical approval

Institutional Review Boards of the Hospital Universitário Prof. Edgard Santos and Weill Cornell Medical College.

## Acknowledgements

We thank Marcelo Quintana and STS Blood Bank for referring subjects to our study; the clinicians at the HTLV-1 clinic for their advice; the members of the Immunology Service for their invaluable assistance and encouragement, especially Dr. Ramon Kruschewsky and Dr. Bernardo Galvão Castro; and Dr. Warren D. Johnson for his support.

## References

- Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-1 infection and associated diseases. *Oncogene* 2005;**24**:6058–68.
- Vrieling H, Reeskink HW. HTLV-1/2 prevalence in different geographic locations. *Transfus Med Rev* 2004;**18**(1):46–57.
- Poiesz BJ, Ruscetti FW, Gaxdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci U S A* 1980;**77**:7415–9.
- Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, et al. The risk of development of HTLV-1-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-1. *J Acquir Immune Defic Syndr* 1990;**3**(11):1096–101.
- Orland JR, Engstrom J, Friley J, Sacher RA, Smith JW, Nass C, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. *Neurology* 2003;**61**:1588–94.
- Cleghorn FR, Manns A, Falk R, Hartge P, Hanchard B, Jack N, et al. Effect of human T-lymphotropic virus type 1 infection on non-Hodkin's lymphoma incidence. *J Natl Cancer Inst* 1995;**87**:1009–14.
- Mahieux R, Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. *Rev Clin Exp Hematol* 2003;**7**(4):336–61.
- Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. *Lancet Inf Dis* 2007;**7**:266–81.
- Mochizuki M, Watanabe T, Yamaguchi K, Tajima K, Yoshimura K, Nakashima S, et al. An uveitis associated with human T-lymphotropic virus type-1 (HTLV-1): seroepidemiological, clinical, and virological studies. *J Infect Dis* 1992;**166**:943–4.
- Takahashi T, Takase H, Urano T. Clinical features of human T-lymphotropic virus type 1 uveitis: a long-term follow up. *Ocul Immunol Inflamm* 2000;**8**:235–41.
- Buggage R. Ocular manifestations of human T-cell lymphotropic virus type 1 infection. *Curr Opin Ophthalmol* 2003;**14**:420–5.
- Morgan OS, Rodgers-Johnson P, Mora C, Char G. HTLV-1 and polymyositis in Jamaica. *Lancet* 1989;**2**(8673):1184–7.
- Osame M, Nakagawa M, Umehara F, Ijichi S, Moritoyo T, Higuchi I, et al. Recent studies on the epidemiology, clinical features and pathogenic mechanisms of HTLV-1 associated myelopathy (HAM/TSP) and other diseases associated to HTLV. *J Neurovirol* 1997;**3**(Suppl. 1):S50–1.
- Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-1. *Lancet* 1989;**1**:441.
- Murphy EL, Wang B, Sacher RA, Friley J, Smith JW, Nass CC, et al. Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-1 and HTLV-II infection. *Emerg Infect Dis* 2004;**10**:109–16.
- Ferraz-Chaoui AK, Atta AM, Atta MLS, Galvao-Castro B, Santiago MB. Study of autoantibodies in patients with keratoconjunctivitis sicca infected by the human T cell lymphotropic virus type 1. *Rheumatol Int* 2010;**30**:775–8.
- Castro N, Oliveira P, Freitas D, Rodrigues Jr W, Muniz A, Carvalho E. Erectile dysfunction and HTLV-1 infection: a silent problem. *Int J Impot Res* 2005;**17**:364–9.
- Castro NM, Freitas DM, Rodrigues Jr W, Muniz A, Oliveira P, Carvalho EM. Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals. *Neurourology* 2007;**33**(2):238–45.

19. Biswas HH, Engstrom JW, Kaidarova Z, Garratty G, Gibble JW, Newman BH, et al. Neurologic abnormalities in HTLV-1- and HTLV-2-infected individuals without overt myelopathy. *Neurology* 2009;**73**:781–9.
20. Leite ACC, Mendonca GAS, Andrada-Serpa MJ, Nascimento OJM, Araujo AQC. Neurological manifestations in HTLV-1-infected blood donors. *J Neurol Sci* 2003;**214**:49–56.
21. Leite AC, Silva MT, Alamy AH, Afonso CRA, Lima MAD, Andrada-Serpa MJ. Peripheral neuropathy in HTLV-1 infected individuals without tropical spastic paraparesis/HTLV-1-associated myelopathy. *J Neurol* 2004;**251**(7):877–81.
22. Grindstaff P, Gruener G. The peripheral nervous system complications of HTLV-1 myelopathy (HAM/TSP) syndromes. *Semin Neurol* 2005;**25**(3):315–27.
23. Caskey MF, Morgan DJ, Porto AF, Giozza SP, Muniz AL, Orge GO, et al. Clinical manifestations associated with HTLV type 1 infection: a cross-sectional study. *AIDS Res Hum Retroviruses* 2007;**23**(3):365–71.
24. Galvao-Castro B, Loures L, Rodrigues LG, Sereno A, Ferreira Junior OC, Franco LG, et al. Distribution of human T-lymphotropic virus type I among blood donors: a nationwide Brazilian study. *Transfusion* 1997;**37**:242.
25. Dourado I, Alcantara LC, Barreto ML, da Gloria Teixeira M, Galvao-Castro B. HTLV-1 in the general population of Salvador, Brazil – a city with African ethnic and sociodemographic characteristics. *J Acquir Immune Defic Syndr* 2003;**34**(5):527–31.
26. Osame M. Review of WHO Kagoshima meeting diagnostic guidelines form HAM/TSP. In: Blattner W, editor. *Human retrovirology: HTLV*. New York: Raven Press; 1990. p. 191–7.
27. Garlet GP, Giozza SP, Silveira EM, Claudino M, Santos SB, Avila-Campos MJ, et al. *Clin Infect Dis* 2010;**50**(3):e11–8.
28. Oliveira P, Castro NM, Carvalho EM. Urinary and sexual manifestations of patients infected by HTLV-1. *Clinics* 2007;**62**(2):191–6.
29. Castro NM, Rodrigues Jr W, Freitas DM, Muniz A, Oliveira P, Carvalho EM. Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-1 carriers. *Adult Urol* 2007;**69**(5):813–8.
30. Oliveira P, Castro NM, Muniz AL, Tanajura D, Brandao JC, Porto AF, et al. Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder. *Urology* 2010;**75**(5):1100–3.
31. Goncalves DU, Guedes AC, Proietti AB, Martins ML, Proietti FA, Lambertucci JR, et al. Dermatologic lesions in asymptomatic blood donors seropositive for human T cell lymphotropic virus type-1. *Am J Trop Med Hyg* 2003;**68**(5):562–5.
32. Jacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. *J Infect Dis* 2002;**186**(Suppl. 2):S187–92.
33. Cooper SA, Schim van der Loeff M, Taylor GP. The neurology of HTLV-1 infection. *Pract Neurol* 2009;**9**:16–26.
34. Nascimento MCF, Primo J, Bittencourt A, Siqueira I, Oliveira Mdf, Meyer R, et al. Infective dermatitis has similar immunological features to human T lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. *Clin Exp Immunol* 2009;**156**:455–62.
35. Yakova M, Lezin A, Dantin F, Lagathu G, Olindo S, Jean-Baptiste G, et al. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. *Retrovirology* 2005;**1**:2–4.
36. Silva MTT, Harab RC, Leite AC, Schor D, Araujo A, Andrade-Serpa MJ, et al. Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection. *Clin Infect Dis* 2007;**44**:689–92.
37. Carvalho EM, Bacellar O, Porto AF, Braga S, Galvao-Castro B, Neva F. Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors. *J Acquir Immune Defic Syndr* 2001;**27**:1–6.
38. Santos SB, Porto AF, Muniz AL, de Jesus AR, Magalhaes E, Melo A, et al. Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-1 asymptomatic carriers. *BMC Infect Dis* 2004;**4**:7.
39. Guerreiro JB, Porto MAF, Santos SB, Lacerda L, Ho JL, Carvalho EM. Spontaneous neutrophil activation in HTLV-1 infected patients. *Braz J Infect Dis* 2005;**9**(6):510–4.
40. Mota A, Nunes C, Melo A, Romeo M, Boasorte N, Dourado I, et al. A case-control study of HTLV-infection among blood donors in Salvador, Bahia, Brazil – associated risk factors and trend towards declining prevalence. *Rev Bras Hematol Hemoter* 2006;**28**(2):120–6.
41. Bagnato F, Butman JA, Mora CA, Gupta S, Yamano Y, Tasciyan TA, et al. Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis. *J Neurovirol* 2005;**11**:525–34.
42. Morgan DJ, Caskey MF, Abbehusen C, Oliveira-Filho J, Araujo C, Porto AF, et al. Brain magnetic resonance imaging white matter lesions are frequent in HTLV-1 carriers and do not discriminate from HAM/TSP. *AIDS Res Hum Retroviruses* 2007;**23**:1499–504.